ALSO READEris Lifesciences IPO subscribed 12% on Day 1 Global Markets - Asian shares rattled by Trump policy worries, dollar soft Tejas Networks IPO subscribed 11 pc on Day 1 Global Markets - European shares fall, sterling dives on Brexit comments Global Markets - European shares edge up as reflation trades questioned
The initial public offer of Eris Lifesciences was subscribed 75 per cent on the second day of the issue today.
The IPO, to raise Rs 1,741 crore, received bids for 1,20,33,096 shares against the total issue size of 1,59,48,750 shares, data available with the NSE showed.
The portion set aside for qualified institutional buyers (QIBs) was subscribed 82 per cent, non institutional investors 3 per cent and retail investors 1.68 times.
Eris Lifesciences last week mopped up Rs 779 crore from 21 anchor investors.
The price band for the share sale has been fixed at Rs 600-603.
The offer, which closes tomorrow, comprises sale of 2.89 crore shares.
The book running lead managers to the offer are Axis Capital, Citigroup Global Markets India and Credit Suisse Securities (India).
Eris Lifesciences is into manufacturing of branded pharmaceutical products in select therapeutic areas.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)